PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

SGLT2 Inhibitors Show No Significant Serious UTI Excess

SGLT2 inhibitorsempagliflozindapagliflozincanagliflozinertugliflozinbexagliflozinurinary tract infectiontype 2 diabetesheart failurechronic kidney diseasemeta-analysisdrug safety Endocrinology / Diabetes / Obesity

Background Information

SGLT2 inhibitors show no significant rise in UTI risk.

The risk of urinary tract infections (UTIs) with SGLT2 inhibitors is unclear despite their common use for type 2 diabetes, heart failure, and chronic kidney disease. SGLT2 inhibitors did not show a statistically significant increase in any UTI (RR 1.08, P = 0.060) or serious/complicated UTI (RR 0.99, P = 0.960). These results indicate no significant rise in UTIs, differentiating between lower-grade urinary events and more severe infections, unlike the known risk of genital infections. SGLT2 inhibitors do not significantly increase UTI risk, distinguishing them from risks of genital infections.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Matteucci A, Di Fusco SA, Bonanni M, Castello L, Aquilani S, Fedele S, Nardi F, Colivicchi F

Citation: Matteucci A, Di Fusco SA, Bonanni M, et al. Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2026;34(2). doi:10.1007/s40199-026-00637-7

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.